• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
CONCLUSIONS: Globally, Lp(a) is measured in a small minority of patients with ASCVD and is highest in black, younger and female patients. More than 25% of patients had levels exceeding the established threshold for increased cardiovascular risk, approximately 50 mg/dL or 125 nmol/L.PMID:36252994 | DOI:10.1136/openhrt-2022-002060
Source: Atherosclerosis - October 17, 2022 Category: Cardiology Authors: Steven E Nissen Kathy Wolski Leslie Cho Stephen J Nicholls John Kastelein Eran Leitersdorf Ulf Landmesser Michael Blaha A Michael Lincoff Ryuichi Morishita Sotirios Tsimikas Junhao Liu Brian Manning Plamen Kozlovski Anastasia Lesogor Tom Thuren Taro Shiba Source Type: research

Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial
CONCLUSIONS: PPV engenders a long-lasting increase in anti-pneumococcal IgG, and to a lesser extent, IgM titres, as well as a transient increase in anti-OxLDL IgM antibodies. However, there were no detectable changes in surrogate markers of atherosclerosis at the 2-year follow-up. Long-term, prospective follow-up of clinical outcomes is continuing to assess if PPV reduces CVD events.PMID:35290813 | DOI:10.1016/j.atherosclerosis.2022.02.011
Source: Atherosclerosis - March 15, 2022 Category: Cardiology Authors: Shu Ren Philip M Hansbro Wichat Srikusalanukul Jay C Horvat Tegan Hunter Alexandra C Brown Roseanne Peel Jack Faulkner Tiffany-Jane Evans Shu Chuen Li David Newby Alexis Hure Walter P Abhayaratna Sotirios Tsimikas Ayelet Gonen Joseph L Witztum John Attia Source Type: research